Last reviewed · How we verify

NCT07271615

Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

Recruiting now NA Last updated 9 December 2025
What this trial tests

NA trial testing Stellate Ganglion Block in Adult Patients Undergoing CABG in 60 participants. Currently enrolling.

Timeline
19 November 2025
Primary endpoint
31 May 2026
31 July 2026

Quick facts

Lead sponsorXijing Hospital
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeprevention
Enrollment60
Start date19 November 2025
Primary completion31 May 2026
Estimated completion31 July 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Xijing Hospital

Who can join

18 and older, any sex, with Adult Patients Undergoing CABG. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the feasibility of preoperative stellate ganglion block in reducing the incidence of postoperative atrial fibrillation in patients undergoing CABG.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stellate Ganglion Block

Trials testing the same drug.

Other Xijing Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07271615.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing